Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Merck Patent Gesellschaft

Meck Patent Gmbh

Norbert Beier

Klaus-Otto Minck

Rolf Gericke

Werner Mederski

Pierre Schelling

Dieter Dorsch

Manfred Baumgarth

Ingeborg Lues

Michael Wolf

Markus Klein

Florian Lang

Rochus Jonas

Hans-Michael Eggenweiler

Lars Thore Burgdorf

Christos Tsaklakidis

Maria Christadler

Mathias Osswald

Johannes Gleitz

Christine G Charon

Thomas Ehring

Bertram Cezanne

Ulrich Emde

Joachim Leibrock

Thomas Fuchss

Michael Gassen

Franz-Werner Kluxen

Johannes Sombroek

Inge Lues

Jonas Rochus

Wolfgang Scholz

Denis Carniato

Daniel Cravo

Andreas Bathe

Christoph Saal

Klaus Otto Minck

Michael Klockow

Karl Lang

Ulrich Betz

Ulrich Graedler

Philipp Lang

Oliver Poeschke

Phillipp Lang

Thorsten Hartig

Helga Drosdat

Hans-Micahel Eggenweiler

Harry Schwartz

Matthias Osswald

Manfred Haumgarth

Stefan Bender

Marian Braendle

The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of &#xdf;-cell compensation.

Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and &#x3b2;-cell dysfunction

Novel heterocyclic compounds of the formula (I), in which R, D, W, T and T' have the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

Heterocyclic carbonyl compounds

The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.

SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas

Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R, R, R, R, R, Rand Rhave the meanings indicated in claim, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases.

Difluorophenyldiacylhydrazide derivatives

Novel heterocyclic compounds of the formula I in which R, R, R, R, R, R, R, R, Rand Rhave the meanings indicated in Claimare activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

Beta-amino acid derivatives for treatment of diabetes

Novel heterocyclic compounds of the formula I in which R, R, R, Rand D have the meanings indicated in Claim, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

Pyridine derivatives useful as glucokinase activators

Novel compounds of the formula (I), in which X has the meaning indicated in Patent Claim, are suitable as antidiabetics.

Glucopyranoside derivatives

The present invention relates to novel compounds of general formula (I) and uses thereof.

5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2

Novel oxadiazole derivatives of the formula (I), in which R, R', Y, X, Xand Xhave the meanings indicated in claim, are kinase inhibitors and can be used for the treatment of diseases and conditions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, in general in all types of fibroses, inflammatory processes, tumours and tumour diseases.

Oxadiazole derivatives for the treatment of diabetes

Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R, Rand Rhave the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.

Heterocyclic indazole derivatives

Novel compounds of the formula (I), in which W, T, R, R, R, R, R, Rand Xhave the meanings indicated in Patent Claim, are suitable as antidiabetics.

[object Object]

Novel compounds of the formula I, in which X, Y, R, R', R, R, R, R, R, R, R, R, R, Rand n have the meanings indicated in Patent Claim, are suitable as antidiabetics 

3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors

Novel heterocyclic compounds of the formula I in which R, R, R, R, R, R, R, Alk and D have the meanings indicated in claimare activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.

N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators

Novel aminoindazolylurea derivatives of the formula I (I), in which R, R, R, R, R, X and Y have the meanings indicated in Claim, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. 

Aminoindazolylurea derivatives

Novel compounds of the formula (I), in which W, T, R, R, R, R, Rand Rhave the meanings indicated in Patent Claim (), are suitable as antidiabetics. 

3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes

Growing community of inventors

Reinheim, Germany

Norbert Beier